ARK Genomic Revolution ETF
ARKG
Chicago Board Options Exchange- -
USD
- -
- -
- -
- -
(- -)
Recent
price
- -
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- ARK Genomic Revolution ETF (ARKG) is an actively managed exchange-traded fund that seeks long-term growth of capital by investing at least 80% of its assets in domestic and foreign equity securities of companies relevant to the genomics revolution theme across sectors including health care, information technology, materials, energy, and consumer discretionary. The fund targets companies focused on extending and enhancing human and other life through technological and scientific advancements in genomics, with core holdings emphasizing precision therapies such as gene therapy and targeted therapeutics; multiomic technologies including DNA sequencing, bioinformatics, and molecular diagnostics; programmable biology like gene editing; and enabling platforms in neural networks, next-generation cloud computing, and adaptive robotics. Top holdings as of late 2025 include Tempus AI Inc. (10.5%), CRISPR Therapeutics AG (10.0%), Twist Bioscience Corp. (5.1%), Recursion Pharmaceuticals Inc. (4.8%), and Personalis Inc. (4.5%), representing approximately 55.8% of the portfolio; the fund typically maintains 40-60 holdings with a weighted average market cap of $8 billion and median market cap of $1 billion. Launched on October 31, 2014, and managed by ARK Investment Management LLC in St. Petersburg, Florida, ARKG provides thematic multi-cap exposure primarily to North American (88.1%) and Western European (11.9%) issuers, with 98.2% allocated to health care and a non-diversified portfolio featuring high active share versus the S&P 500. In 2024, ARK Invest Europe launched a UCITS version of ARKG following the 2023 acquisition and rebranding of Rize ETF, expanding access for European investors alongside ARKK and a new AI & Robotics ETF under Cathie Wood's leadership. Recent portfolio shifts in late 2024 and 2025 include significant increases in Tempus AI shares across ARK funds, reflecting emphasis on AI-driven healthcare genomics, alongside additions like Guardant Health and Personalis; additionally, holdings such as Tempus AI pursued strategic actions including the acquisition of AI-powered digital pathology firm Paige and FDA clearances for cardiac imaging and RNA diagnostics.